DUBLIN, Sept. 10, 2021 /PRNewswire/ -- Gain comprehensive access to over 850 cardiovascular partnering deal records from this report "Global Cardiovascular Partnering 2014-2021: Deal Trends, Players and Financials" that has been added to ResearchAndMarkets.com's offering.
Global Cardiovascular Partnering 2014 to 2021 provides the full collection of Cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Cardiovascular partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Cardiovascular partnering agreement structure
Cardiovascular partnering contract documents
Top Cardiovascular deals by value
Most active Cardiovascular dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.
The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Cardiovascular dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Cardiovascular dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Cardiovascular deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Cardiovascular deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Cardiovascular partnering deals by specific Cardiovascular target announced since 2014. The chapter is organized by specific Cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Cardiovascular partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Cardiovascular partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cardiovascular technologies and products.
The report is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.
Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials includes:
Trends in cardiovascular dealmaking in the biopharma industry since 2014
Analysis of cardiovascular deal structure
Access to headline, upfront, milestone and royalty data
Access to over 850 cardiovascular deal records
The leading cardiovascular deals by value since 2014
The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications.
In Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials, the available deals are listed by:
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 850 cardiovascular deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Cardiovascular dealmaking
2.2. Cardiovascular partnering over the years
2.3. Cardiovascular partnering by deal type
2.4. Cardiovascular partnering by industry sector
2.5. Cardiovascular partnering by stage of development
2.6. Cardiovascular partnering by technology type
2.7. Cardiovascular partnering by therapeutic indication
Chapter 3 -Financial deal terms for Cardiovascular partnering
3.2. Disclosed financials terms for Cardiovascular partnering
3.3. Cardiovascular partnering headline values
3.4. Cardiovascular deal upfront payments
3.5. Cardiovascular deal milestone payments
3.6. Cardiovascular royalty rates
Chapter 4 - Leading Cardiovascular deals and dealmakers
4.2. Most active in Cardiovascular partnering
4.3. List of most active dealmakers in Cardiovascular
4.4. Top Cardiovascular deals by value
Chapter 5 - Cardiovascular contract document directory
5.2. Cardiovascular partnering deals where contract document available
Chapter 6 - Cardiovascular dealmaking by therapeutic target
6.2. Deals by Cardiovascular therapeutic target
4D Molecular Therapeutics
36 Strategies General Trading
A*STAR Agency for Science
Technology and Research
Abbott Vascular Devices
Actuated Cardio Engineering
ADAS 3D Medical
Advanced BioScience Laboratories
Advanced Cardiac Therapeutics
Advanced Catheter Therapies
Advanced Cooling Therapy
Akums Drugs and Pharmaceuticals
Allegiance Health Foundation
American College of Emergency Physicians
American College of Physicians Foundation
American College of Surgeons
American Heart/Stroke Association
American Heart Association
Angel Medical Systems
AOP Orphan Pharmaceuticals
Apollo Hospitals Group
Argon Medical Devices
Arterial Health International
Arterial Remodeling Technologies
Ashland-Boyd County Health Department
Aspire Health Science
AstraZeneca HealthCare Foundation
Baker IDI Heart and Diabetes Institute
Beijing Leadman Biochemistry
Beijing SL Pharma
Biovic Sdn bhd
Boston Medical Center
Brigham and Women's Hospital
Brigham Young University
California Institute for Regenerative Medicine
California Institute of Technology
Canadian Institutes of Health Research
Cardio3 Biosciences Asia Holdings
Cardiovascular Cell Therapy Research Network
Cardiovascular Research Foundation
Case Western Reserve University
CAS Medical Systems
Catherine's Health Center
Cedars-Sinai Health System
Cedars-Sinai Medical Center
Cell and Gene Therapy Catapult
Center for Biomarker Research in Medicine
Center for Connected Health
Centers for Medicare and Medicaid Services
Charles River Laboratories
Children's Heart Foundation
Children's Hospital Boston
Children's Hospital of Philadelphia
Children's Medical Research Institute
Children's Hospital Oakland Research Institute (CHORI)
China Grand Pharmaceutical
China Medical System
Chinese Future Industry Investment Fund
Chinese Society of Cardiology
Chong Kun Dang
Christiana Care Health System
Colibri Heart Valve
College of Life Science of Northwest University
Columbia University Medical Center
Corindus Vascular Robotics
DaVinci Biomedical Research Products
Department of Defense
Department of Health and Human Services
Diablo Clinical Research
DiA Imaging Analysis
Dr. Reddy's Laboratories
Drukier Institute for Children's Health
Duke-NUS Graduate Medical School Singapore
Duke Clinical Research Institute (DCRI)
Duke University Medical Center
Elkhorn Logan Valley Public Health Department
Enterprise Partners Venture Capital
Erasmus University Medical Center
Eurolab Especialidades Medicinales de Eurofar
European Innovation Council
Event Cardio Group
Feinstein Institute for Medical Research
Fine Foods & Pharmaceuticals N.T.M.
First Check Diagnostics
Food and Drug Administration (FDA)
Foundation for Community Partnerships
Frankfurt University Hospital
Fujifilm medical systems
Fundacion Progreso y Salud
Fu Wai Hospital
Geisinger Medical Center
George Washington University
German Ministry for Education and Research
Global Genomics Group
Guangdong Provincial People's Hospital
Hadasit Medical Research Services and Development
Hainan Savy Akers Biosciences
Hainan Savy Investment Management
Hainan Sihuan Pharmaceutical
Harbin Gloria Pharmaceuticals
Harvard Apparatus Regenerative Technology
Harvard Pilgrim Health Care
Harvard Stem Cell Institute
Healthcare Technology Innovation Centre (Chennai)
Health Sciences Research Institute Germans Trias i Pujol Foundation
HealthTrust Purchasing Group
Heart Rhythm Society
HemCon Medical Technologies
Henry Ford Health System
HLH BioPharma Vertriebs
Hospices Civils de Lyon
Hospital of University of Strasbourg
iBIO Institute's PROPEL Center
Icahn School of Medicine at Mount Sinai
Imperial College London
Imricor Medical Systems
Independent Medical Coop
Indiana Biosciences Research Institute
Innovation Network Corporation
Innovative Genomics Initiative (IGI)
Integrated DNA Technologies
Janssen Research & Development
Johns Hopkins Medicine (JHM)
Johns Hopkins University
Johnson & Johnson
Johnson & Johnson Innovation
Kennedy Trust For Rheumatology Research
King's College Hospital
KOL Bio Medical Instruments
Korea Animal Medical Science Institute
Kowa Pharmaceuticals America
Kyowa Hakko Kirin
Laboratory Corporation of America
La Jolla Capital
La Jolla Pharmaceutical
Lantheus Medical Imaging
Linear Health Sciences
Lombard Medical Technologies
LSU Health Sciences Center
Luye Pharma Group
Magnum Cell Therapies
Mallory Community Health Center
Maquet Medical Systems
Massachusetts General Hospital
Massachusetts Institute of Technology
Matthew Walker Comprehensive Health Center
MD Anderson Cancer Center
MedPac Asia Pacific
Merck and Co
Merus Labs International
Micro Interventional Devices
Micro Medical Solutions
MicroPort Sorin CRM (Shanghai)
Ministry of Health (Saudi Arabia)
Mitsubishi Tanabe Pharma
Montreal Heart Institute
National Cancer Center
National Center for Cardiovascular Diseases
Lung and Blood Institute
National Institute of Neurological Disorders and Stroke
National Institute on Drug Abuse (NIDA)
National Institutes of Health
National Institutes of Health Center for Regenerative Medicine
National Organization for Rare Disorders
National Physical Laboratory
National Research Council Industrial Research Assistance Program
National Science Foundation
National University of Singapore
NeuroVive Pharmaceutical Asia
New England Research Institutes
New York Genome Center (NYGC)
Nissan Chemical Industries
North Carolina State University
North Georgia Healthcare
Northwestern Medicine Bluhm Cardiovascular Institute
Northwestern Medicine Developmental Therapeutics Institute
Nutricare Costa Rica
Ohio State University
On-X Life Technologies
Ontario Institute for Cancer Research
And Many More Companies!
For more information about this report visit https://www.researchandmarkets.com/r/9ip0pv
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets